OpGen and Femasys: Pre-Market Action Unveiled
- September 29th, 2023
- 524 views
Shares of OpGen, Inc. (Nasdaq: OPGN) surged by more than 100% in pre-market trading following a regulatory filing with the Securities and Exchange Commission (SEC), requesting the SEC's consent to withdraw the company's Registration Statement on Form S-1, along with all related amendments and exhibits. It's important to note that the Registration Statement had not been declared effective, and no securities covered by it had been issued or sold.
$OPGN was trading at $0.48 pre-market, marking a substantial gain of $0.28 (+139.65%).
In other news, Femasys Inc. (Nasdaq: FEMY), a notable healthcare company, received a positive review from HC Wainwright & Co., which upheld its "Buy" rating on the stock and increased the price target from $5 to $13.
Considering Thursday's closing price of $1.52 for $FEMY, the revised price target suggests a substantial potential upside of $11.48 per share or approximately 753.68%, based on the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login